In general, patients should start to see relief from their symptoms within 2-4 weeks after beginning treatment, and maximum benefit achieved at 12 weeks post-injection
If you add 2mL of water to the 5,000mcg of BPC-157, your vial now contains 2mL of solution
Low Starting Amount Amount per injection: 1.0 mg 3 units (0.03 mL) on a U-100 insulin syringe Frequency: Once daily, under the skin (MonFri, weekends off) Cycle length: 812 weeks, then 24 weeks off Sources: [1] Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data NIH / PMC
What the Evidence Actually Shows Being precise here is what keeps this guide honest and useful
The potential benefits for recovery are intriguing, but they must be weighed against the very real risks of an unregulated market
(a) Gastrointestinal trials (Ulcerative Colitis) A Croatian research group conducted: A phase I safety study in healthy men A phase II trial of a rectal BPC-157 formulation for mildmoderate ulcerative colitis These are only available as abstracts and drug summaries , not as full peer-reviewed publications with methods, statistics, or adverse event profiles